{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:04:08Z","timestamp":1787598248752,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102869","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T21:31:45Z","timestamp":1614288705000},"page":"102869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature."],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-846X","authenticated-orcid":false,"given":"Mario","family":"Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-3723","authenticated-orcid":false,"given":"Luis Alfonso","family":"Zarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Agudelo-Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Torres-Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-0266","authenticated-orcid":false,"given":"Elkin","family":"Garcia-Cifuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-0018","authenticated-orcid":false,"given":"Oscar","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2021.102869_bib0008","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2021.102869_bib0003","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14737175.2019.1648210","article-title":"Controversies in the management of neuromyelitis optica spectrum disorder","volume":"19","author":"Bruscolini","year":"2019","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.msard.2021.102869_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"10206","key":"10.1016\/j.msard.2021.102869_bib0010","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.msard.2021.102869_bib0031","article-title":"The efficacy and tolerability of azathioprine for patients with neuromyelitis optica spectrum disorder: a systematic review","volume":"92","author":"Espiritu","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.102869_bib0014","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jrsm.1056","article-title":"Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions","volume":"4","author":"Higgins","year":"2013","journal-title":"Res. Synth Methods"},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.102869_bib0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","article-title":"Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders","volume":"324","author":"Ip","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2021.102869_bib0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2015","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2021.102869_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.102869_bib0019","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.102869_bib0013","article-title":"Revisiones sistem\u00e1ticas para la evaluaci\u00f3n de intervenciones que incluyen estudios no aleatorizados","author":"Mu\u00f1oz Velandia","year":"2018","journal-title":"Consideraciones Metodol\u00f3gicas"},{"key":"10.1016\/j.msard.2021.102869_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.npbr.2019.12.003","article-title":"A study on patients with neuromyelitis optica spectrum disorder from Eastern India","volume":"35","author":"Mukherjee","year":"2020","journal-title":"Neurol. Psychiatry Brain Res."},{"key":"10.1016\/j.msard.2021.102869_bib0018","unstructured":"Network S.I.G. Methodology checklist 2: controlled trials. 2012."},{"issue":"9","key":"10.1016\/j.msard.2021.102869_bib0026","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2021.102869_bib0002","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2014.1581","article-title":"Seroprevalence of aquaporin-4\u2013IgG in a northern California population representative cohort of multiple sclerosis","volume":"71","author":"Pittock","year":"2014","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.102869_bib0009","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2021.102869_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","article-title":"Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"Sato","year":"2012","journal-title":"Arq Neuropsiquiatr."},{"issue":"4","key":"10.1016\/j.msard.2021.102869_bib0028","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102869_bib0017","first-page":"355","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.msard.2021.102869_bib0007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.102869_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2021.102869_bib0012","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102869_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2021.102869_bib0015","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2021.102869_bib0016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102869_bib0023","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"22","key":"10.1016\/j.msard.2021.102869_bib0011","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102869_bib0027","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2021.102869_bib0024","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol. Belg."},{"issue":"5","key":"10.1016\/j.msard.2021.102869_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.102869_bib0029","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0961203320905668","article-title":"Clinical features of transverse myelitis associated with systemic lupus erythematosus","volume":"29","author":"Zhang","year":"2020","journal-title":"Lupus"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:26Z","timestamp":1761900746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"alternative-id":["S2211034821001358"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102869","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102869"}}